Weekly vs. Every-3-Week cisplatin: which is safer for head and neck cancer?
NCT ID NCT02994069
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving cisplatin chemotherapy weekly alongside radiation causes fewer severe side effects than the standard every-3-week schedule in people with head and neck cancer. About 80 participants will receive one of the two schedules. The study also looks at how oxidative stress markers relate to side effects. Results could help doctors choose a safer treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cisplatin (chemotherapy) given with radiation therapy
What this could lead to
If successful, this could show that weekly cisplatin is safer than the standard every-3-week schedule while still controlling the cancer.
What could go wrong
This is a small phase 2 trial with only 80 participants, so results may not apply to all patients. The study is also not testing a new drug, just a different dosing schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kentucky
Lexington, Kentucky, 40536, United States